166 related articles for article (PubMed ID: 19682524)
1. Characterization of two novel tritiated radioligands for labelling Neuropeptide FF (NPFF(1) and NPFF(2)) receptors.
Talmont F; Garcia LP; Mazarguil H; Zajac JM; Mollereau C
Neurochem Int; 2009 Dec; 55(8):815-9. PubMed ID: 19682524
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the mouse NPFF2 receptor.
Talmont F; Moulédous L; Piedra-Garcia L; Schmitt M; Bihel F; Bourguignon JJ; Zajac JM; Mollereau C
Peptides; 2010 Feb; 31(2):215-20. PubMed ID: 19944730
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of a human receptor for neuropeptide FF and related peptides.
Kotani M; Mollereau C; Detheux M; Le Poul E; Brézillon S; Vakili J; Mazarguil H; Vassart G; Zajac JM; Parmentier M
Br J Pharmacol; 2001 May; 133(1):138-44. PubMed ID: 11325803
[TBL] [Abstract][Full Text] [Related]
4. [(125)I]EYF: a new high affinity radioligand to neuropeptide FF receptors.
Gouardères C; Mollereau C; Tafani JA; Mazarguil H; Zajac JM
Peptides; 2001 Apr; 22(4):623-9. PubMed ID: 11311733
[TBL] [Abstract][Full Text] [Related]
5. Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.
Elhabazi K; Humbert JP; Bertin I; Schmitt M; Bihel F; Bourguignon JJ; Bucher B; Becker JA; Sorg T; Meziane H; Petit-Demoulière B; Ilien B; Simonin F
Neuropharmacology; 2013 Dec; 75():164-71. PubMed ID: 23911743
[TBL] [Abstract][Full Text] [Related]
6. Assessing activation of the human neuropeptide FF2 receptor with a non-radioactive GTP binding assay.
Engström M; Närvänen A; Savola JM; Wurster S
Peptides; 2004 Dec; 25(12):2099-104. PubMed ID: 15572197
[TBL] [Abstract][Full Text] [Related]
7. Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands.
Gouardères C; Quelven I; Mollereau C; Mazarguil H; Rice SQ; Zajac JM
Neuroscience; 2002; 115(2):349-61. PubMed ID: 12421602
[TBL] [Abstract][Full Text] [Related]
8. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide FF analog RF9 is not an antagonist of NPFF receptor and decreases food intake in mice after its central and peripheral administration.
Maletínská L; Tichá A; Nagelová V; Spolcová A; Blechová M; Elbert T; Zelezná B
Brain Res; 2013 Mar; 1498():33-40. PubMed ID: 23291266
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells.
Mollereau C; Mazarguil H; Zajac JM; Roumy M
Mol Pharmacol; 2005 Mar; 67(3):965-75. PubMed ID: 15608144
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide FF receptors: structure-activity relationship and effect of morphine.
Payza K; Akar CA; Yang HY
J Pharmacol Exp Ther; 1993 Oct; 267(1):88-94. PubMed ID: 8229791
[TBL] [Abstract][Full Text] [Related]
12. Study of the N-terminal part of peptidic selective NPFF₂ agonists.
Mazarguil H; Mollereau C; Czaplicki G; Zajac JM
Peptides; 2012 Sep; 37(1):157-60. PubMed ID: 22813580
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives.
Vyas N; Mollereau C; Chevé G; McCurdy CR
Peptides; 2006 May; 27(5):990-6. PubMed ID: 16490282
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon.
Fang Q; Guo J; Chang M; Chen LX; Chen Q; Wang R
Peptides; 2005 May; 26(5):791-7. PubMed ID: 15808909
[TBL] [Abstract][Full Text] [Related]
15. Are neuropeptides FF and SF neurotransmitters in the rat?
Roumy M; Gouardères C; Mazarguil H; Zajac JM
Biochem Biophys Res Commun; 2000 Sep; 275(3):821-4. PubMed ID: 10973805
[TBL] [Abstract][Full Text] [Related]
16. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies of RFamide peptides reveal subtype-selective activation of neuropeptide FF1 and FF2 receptors.
Findeisen M; Rathmann D; Beck-Sickinger AG
ChemMedChem; 2011 Jun; 6(6):1081-93. PubMed ID: 21548099
[TBL] [Abstract][Full Text] [Related]
18. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
19. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist.
Fang Q; Guo J; He F; Peng YL; Chang M; Wang R
Peptides; 2006 Sep; 27(9):2207-13. PubMed ID: 16762456
[TBL] [Abstract][Full Text] [Related]
20. [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor.
Klotz KN; Falgner N; Kachler S; Lambertucci C; Vittori S; Volpini R; Cristalli G
Eur J Pharmacol; 2007 Feb; 556(1-3):14-8. PubMed ID: 17126322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
